Houston-based biotech firm CrossBridge Bio has raised $10 million in funding to support its pioneering work on dual-payload antibody-drug conjugates (ADCs) for targeted cancer treatments.
- Funding Overview: Raised $10 million in its latest round, led by TMC Venture Fund and CE-Ventures. Additional investors include Portal Innovations, Alexandria Venture Investments, Linden Lake Labs, and other pre-seed supporters.
- Company Background: Led by CEO Michael Torres, the company focuses on dual-payload ADCs to improve cancer treatment precision.
- Use of Funds: The funds will be used to advance CBB-120’s clinical development, expand the ADC pipeline, and strengthen the proprietary linker technology.
CrossBridge Bio is pushing the boundaries of cancer treatment, providing more precise and effective options for patients facing difficult-to-treat cancers.
